Synthesis and evaluation of some steroidal oximes as cytotoxic agents: Structure/activity studies (I)
Jian-Guo Cui , Lei Fan , Li-Liang Huang , Hong-Li Liu , Ai-Min Zhou Introduction A variety of steroids with unusual and interesting structures have been isolated from marine sponges recently [1] [2] [3] . Among these steroidal compounds, marine steroids with oxime groups have been reported rarely. Two steroidal oximes, (6E)-hydroximino-24-ethylcholest-4-en-3-one and (6E)-hydroximinocholest-4-en-3-one, were isolated from Cinachyrella alloclada and C. apion [4] in 1997, and another steroidal oxime, (3E)-hydroximinocholest-4-en-6-one, was isolated from marine sponge Cinachyrella australiensis of South China Sea [5] in 2005. The structures of the three compounds are shown in Fig. 1 . Studies have revealed that these steroids exert interesting biological activities. For example, the compound 3 displays antiviral function to hepatitis virus (Hep G2) in vitro [5] and the compound 2 exerts cytotoxic activities against several types of cancer cells such as P-388 (murine leukemia), A-549 (human lung carcinoma), HT-29 (human colorectal adenocarcinoma) and MEL-28 (human myeloma) tumor cells [6] .
In recent years, several 6-hydroximinosteroid analogues have been synthesized and evaluated for their cytotoxicity [7] [8] [9] . Interestingly, studies have revealed that the cytotoxicity of these compounds against cancer cells is dependent on the location of the hydroximino group on the steroidal nucleus. The parental steroids with a hydroximino group located at a different position show a remarkable difference in their cytotoxicities, suggesting the importance of a side chain location on a steroid compound in its biological functions. In this report we present more evidence that the cytotoxicity of steroidal oximes we synthesized is not only dependent on the location of a hydroximino group but also the type of a side chain at position 17 on the parental steroid. Our results may provide useful information for the design of chemotherapeutic drugs. 
Results and discussion

Chemistry
To determine the effect of the type of a side chain and the hydroximino position on the biological role of a steroidal compound, we have synthesized several analogues of steroidal oximes with the variation of the side chain at position 17 and the hydroximino group on the A ring or B ring by using cholesterol, stigmasterol and ␤-sitosterol.
Synthesis of analogues of (3E)-hydroximino-4-en-6-one steroids (Scheme 1)
The steroidal oxime 3 and its analogues, with a hydroxymino group on the A ring, were synthesized in two steps according to the sequence shown in Scheme 1. First, the compound 4a was converted to the corresponding 4-en-3,6-dione (5a) via oxidation with pyridinium chlorochromate (PCC) in CH 2 Cl 2 . Next, the oxime 3 was produced in a yield of 87% by the reaction of 5a with hydroxylamine hydrochloride in ethanol in the presence of NaOAc. At the same time, the compound 2 was obtained as a byproduct in 3% yield. The structure of 3 and 2 was confirmed by analysis of the proton and carbon NMR chemical shifts at C-2 and C-7. Resonances showing H-2 at 3.095 ppm (dd, J = 18.0 and 3.8 Hz) and C-3 at 155.808 ppm demonstrated a position of 3-hydroxymino in 3, while the chemical shifts found for 7-␤H and C-6 at 3.437 ppm (1H, dd, J = 15.9 and 4.6 Hz) and 149.173 ppm, respectively were indicative of the E-configuration of 6-hydroxymino in 2.
Synthesis of analogues of (6E)-hydroximino-4-en-3-one steroids (Scheme 2)
Seven steps were needed to synthesize compound 1 as reported in Ref. [4] . Here, we introduce a new synthetic method for the steroidal oxime compounds 1, 2 and 10 with higher overall yields and fewer synthetic steps [10] .
The cholest-4-en-3,6-dione (5a) was converted to 8a by selective reduction using NaBH 4 in the presence of CoCl 2 according to the synthetic method we developed. The structure of 8a was confirmed by comparing IR and 1 H NMR spectra with those of the analogous compound that was analyzed previously. The oxime 9a was generated by the reaction of 8a with hydroxylamine hydrochloride in ethanol in the presence of NaOAc. At the same time, Z-isomer of 9a was yielded in the reaction with a lower yield (3%). The oxidation of 9a with a Jones' reagent in acetone produced the compound 2.
Synthesis of analogues of (7E)-hydroximino-5-en-3-ol steroids (Scheme 3)
We designed and synthesized a series of analogues of (7E)-hydroximino-5-en-3-ol steroids. These compounds have a hydroxyimino group at C-7 on the B ring. The following steps were used to synthesize these compounds. First, the 3␤-hydroxy group of 4a was protected by forming the acetic ester (11a), which was then converted to a 5-ene-7-one 12a by oxidation with CrO 3 in pyridine and dichloromethane for 25 h at ambient temperature. The yield of the product was about 71%. The hydrolysis of 12a with alcoholic K 2 CO 3 obtained the compound 13a in a yield of 73%. Final oximination of 12a and 13a 
Synthesis of analogues of (3E)-hydroximino-4-ene steroids (Scheme 4)
The compounds 18a-c lacking of a substituted group on B ring were synthesized from the compound 4a which was oxidized to 5-ene-3-one (16a) with Jones' reagent in acetone and subsequent treatment with oxalic acid gave 4-ene-3-one (17a) in 83% yield. Oximination of 17a with hydroxylamine hydrochloride produced the hydroximinosteroid analogues (18a) in 73% yield.
Synthesis of analogues of (3E,6E)-dihydroximino-4-ene steroids (Scheme 5)
We synthesized steroid analogues with two hydroxyimino groups on the steroidal rings. Two hydroxyimino groups were introduced by oximination of 5a and b in the presence of superfluous hydroxylamine hydrochloride to generate the compound 19a and b.
3E-Hydroximinocholest-4-en-6-ol
The compound 20 as shown in Scheme 6 was produced by the reduction of the compound 3. In the presence of CeCl 3 ·7H 2 O as an additive in the reaction, the compound 20 with 6␤-OH was obtained as a major product.
Biological evaluation
To evaluate the effect of the location of the hydroximino group(s) and the type of a side chain at position 17 on the biological functions of steroidal analogues, we determined the cytotoxicity of these compounds to a variety of cancer cell types such as Sk-Hep-1 (human liver carcinoma cell line), H-292 (human lung carcinoma cell line), PC-3 (human prostate carcinoma cell line) and Hey-1B (human ovarian carcinoma cell line) cells. Interestingly, we found that the biological activity of a steroidal oxime was significantly dependent on the location of the hydroximino group(s) and the type of a side chain at position 17 on the parental steroid. The results, expressed as IC 50 values in g, are summarized in Table 1 .
Apparently the structure of a side chain at position 17 on the steroidal oxime plays an important role in its cytotoxicity against cancer cells. An increased antineoplastic activity among these analogueues was observed along with the order of the side chain attached at position 17: cholesterol-type side chain (2, 15a, 19a) >stigmasterol-type side chain (7, 15b, 19b ) >sitosterol-type side chain (1, 19c) . The presence of a cholesterol-type side chain appears to be necessary for the biological activity. The analogues 2, 7, 1, with an oxime group at C-6, showed a remarkable increase in their cytotoxic activity in comparison with the analogues 3, 6b, 6c, which have an oxime group at C-3. The compound 18a-c without any substitute group on ring B, were found no obvious cytotoxicity against these cancer cells. The conversion of a hydroxyl group to a keto group at C3 resulted in a dramatic loss of cytotoxic activity, suggesting the importance of the hydroxyl group in the biological function of a steroidal oxime (comparing the IC 50 values of 9a/2, 9b/7, 9c/1 and 20/3 in Table 1 ). This result is different from the conclusion obtained by Rodriguez and co-workers [6] . The reason for that is under investigation.
Compounds 2 and 7, with a hydroximino group at C-6, showed a slight increase in their cytotoxic activity when compared to compound 15a and 15b with the same group at C-7 (except of Sk-Hep-1 and Hey-1B cell lines for 2/15a). However, after the 3-hydroxy on 15a or 15b was acetylated, the cytotoxic activity of the compounds was markedly decreased (the IC 50 values of 15a/14a, 15b/14b in Table 1 ).
Compound 19a, with a cholesterol-type side chain and two oxime groups at C-3 and C-6, showed a slight increase in its cytotoxicity against Sk-Hep-1 and Hey-1B cells in comparison of compound 2 with the same side chain at position 17, a keto at C-3 and a oxime group at C-6. However, 19b with a stigmasterol-type side chain and a similar steroidal nucleus was less active than analogues 7 of compound 2. Furthermore, conversion of the oxime group at C- 6 (19a, 19b ) to a keto (3, 6b) caused a loss of activity indicating that an oxime on ring B (analogues 2, 7, 15a, 15b, 19a and 19b) or a hydroxy group Scheme 6 -Reagents: (a) NaBH 4 /CH 3 OH, CeCl 3 ·7H 2 O (20: 82%).
Experimental
Chemistry
The sterol and NaBH 4 were purchased from the Merck Co. All chemicals and solvents were analytical grade and solvents were purified by general methods before being used. Melting points were determined on an X 4 apparatus and were uncorrected. Infrared spectra were measured with a Nicolet FT-360 Spectrophotometer. The 1 H and 13 C NMR spectra were recorded in CDCl 3 on a Bruker AV-500 spectrometer at working frequencies 500 and 125 MHz, respectively. Chemical shifts are expressed in ppm (ı) values and coupling constants (J) in Hz. The cell proliferation assay was performed by a MTS method using 96-well plates in Beckman coulter LD400 AD/LD analysis spectrometer.
Compounds 1, 2 and 7 were prepared according to Ref. [10] . -4-en-3,6-dione (5a) Pyridinium chlorochromate (PCC) (2.564 g, 2.0 mmol) was added to a solution of sitosterol (4c) Cholest -4-en-3,6-dione (5b) PCC ( -4,22-dien-3,6-dione (5c) 5c was prepared similarly according to the procedure of 5a. In the reaction, the compound 2 was obtained as a byproduct in 3.4% yield.
24-Ethylcholest
Stigmast
(3E)- The preparing method is similar to 3, yield 70.6%; Â mp 215-216 • C; IR(KBr) (cm −1 ): 3289, 3040, 2954, 2864, 1675, 1581, 1454, 1238, 972 
(3E)-Hydroximino-24-ethylcholest-4-en-6-one (6c)
The preparing method is similar to 3, yield 79.6% 
3-Hydroxycholest-5-en-7-one acetate (12a)
4.400 g CrO 3 was dissolved in a mixture of 8.8 mL pyridine and 60 mL CH 2 Cl 2 . After stirring for 10 min, a sulution of 13 (0.640 g) in 20 mL CH 2 Cl 2 was added slowly. The mixture was stirred at room temperature for 25 h. The reaction mixture was filtered and filtrate was neutralized with 5% HCl, washed (NaCl, NaHCO 3 , and water), dried with anhydrous sodium sulfate, and evaporated under reduced pressure. 
3-Hydroxy-24-ethylcholest-5,22-dien-7-one acetate (12b)
Yield
3-Hydroxycholest-5-en-7-one (13a)
K 2 CO 3 solution (13%) of 15 mL was added to a solution of 12a (0.500 g) in CH 3 OH (30 mL) at room temperature. The reaction mixture was heated under reflux for 4 h. Then the reaction was terminated and the majority of solvent was evaporated under reduced pressure. CH 2 Cl 2 of 60 mL was added to dissolve a solid and the resulting solution was washed with cold water and saturated brines. After drying over anhydrous sodium sulfate, the solvent was removed under reduced pressure, and the resulting crude product was purified by chromatography on silica gel using petroleum ether (60-90 • C)/EtOAc (2:1) -5,22-dien-3-hydroxy-7-one (13b) Yield 95%, Â mp 153-155 • C; IR(KBr) (cm −1 ): 2962, 2872, 1728, 1675, 1458, 1377, 1254, 1037 (7Z)- Compound 12a (75 mg) was dissolved in 10 mL 95% CH 3 CH 2 OH. After the mixture was stirred for 5 min, CH 3 COONa·3H 2 O (23 mg) and NH 2 OH·HCl (18 mg) were added to the solution. The mixture was stirred for 3.5 h at room temperature. After removal of the majority of solvent, proper water was added into the reaction mixture, and the product was extracted with ethyl acetate (3× 15 mL). The combined extracts were washed with saturated brine, dried with anhydrous sodium sulfate, and evaporated under reduced pressure. The residue was subjected to column chromatography (silica gel, ethyl acetate/petroleum ether (60-90 • C) 1:6) to afford 73 mg of 14a (95%) as white solid, Â mp 136-137 • C; IR(KBr) (cm −1 ): 3469, 2954, 2872, 1719, 1670, 1466, 1389, 1262, 1037, 956 (7Z)- Yield 93%, Â mp 140-142 • C; IR(KBr) (cm −1 ): 3407, 2958, 2872, 1732, 1662, 1467, 1368, 1246, 1037, 972 (7Z)- NaOH solution (0.25 mol/L) of 1.3 mL was added to a solution of 13a (83 mg) in 95% CH 3 CH 2 OH (15 mL) at room temperature. After the mixture was stirred for 10 min, NH 2 OH·HCl (40 mg) were added to the solution, and the mixture was heated at 78 • C for 11 h. After removal of the majority of solvent, proper water was added into the reaction mixture, and the product was extracted with ethyl acetate (3× 15 mL). The combined extracts were washed with saturated brine, dried with anhydrous sodium sulfate, and evaporated under reduced pressure. The residue was recrystallized and 84 mg of 15a (99%) was obtained as a white crystal, Â mp 235-236 • C; IR(KBr) (cm −1 ): 3378, 2937, 2864, 1711, 1466, 1384, 1262, 1172, 1021, 959, 796 (7-C), 153.5(5-C), 112.8(6-C), 71.2(3-C), 54.8(17-C), 50.3(14-C), 49.8(13-C), 42.9(4-C), 42.2(9-C), 39.5(8-C), 38.6(10-C), 38.4(24-C), 38.0(12-C), 36.7(1-C), 36.2(22-C), 35.6(20-C), 31.3(2-C), 28.3(16-C), 28.0(25-C), 27.2(15-C), 23.8(23-C), 22.8(26-C), 22.6(27-C), 20.8(11-C), 19.0(21-C), 18.0(19-C), 12.2(18-C) .
24-Ethylcholest
(7Z)- Yield 99%, Â mp 232-233 • C; IR(KBr) (cm −1 ): 3378, 2937 , 1711 , 1466 , 1384 , 1262 , 1172 , 1021 1 H NMR(CDCl 3 ) ı: 0.739(s, 3H, 18-CH 3 ), 0.821 (d, 3H, J = 6.5, or 27-CH 3 ), 0.828(t, 3H, J = 7.5, 0.870(d, 3H, J = 6.5, or 27-CH 3 ), 1.060(d, 3H, J = 6.6, ), 1.149(s, 3H, 1H, 5.046(dd, 1H, J = 15.0, 8.5, 5.200(dd, 1H, J = 15.0, 9.0, 6.566(s, 1H, -4-en-3-one (17a) The Jones' reagent of 1 mL (0.267 mol/L) was gradually added into the solution of 4a (386 mg, 1 mmol) in 50 mL of acetone in 10 min. The reaction mixture was stirred at 0 • C for 15 min and then neutralized with 10% K 2 CO 3 solution. The majority of solvent was evaporated under reduced pressure and then the product was extracted with ethyl acetate (3× 20 mL). The combined extracts were washed with saturated brine, dried with anhydrous sodium sulfate, and evaporated under reduced pressure. The crude product was recrystallized in CH 3 OH to obtain 16a as a white crystal. The white crystal was dissolved in 5 mL 95% CH 3 CH 2 OH, and subsequent treatment with oxalic acid gave cholest-4-en-3-one 17a as pale yellow crystals in 89% yield. Â mp 84-85 • C; IR(KBr) (cm −1 ): 3019, 2945, 2864, 1670, 1609, 1462, 1376, 1333, 1266, 1225, 1192, 1026, 951, 922, 865 -4,22-dien-3-one (17b) Yield 85%, Â mp 121-122 • C; IR(KBr) (cm −1 ): 2969, 2937, 2871, 1679, 1619, 1462, 1446, 1435, 1384, 1270, 1229, 994, 961, 868 -4-en-3-one (17c) Yield 85%, Â mp 161-163 • C; IR(KBr) (cm −1 ): 2957, 2039, 2867, 2852, 1681, 1620, 1466, 1438, 1384, 1367, 1271, 1120, 1030, (3E)- Compound 17a (60 mg, 0.156 mmol) was dissolved in 10 mL 95% CH 3 CH 2 OH. After the mixture was heated to 60 • C, CH 3 COONa·3H 2 O (25 mg, 0.18 mmol) and NH 2 OH·HCl (15 mg, 0.21 mmol) were added into the solution. The mixture was stirred for 1 h at 60 • C. Then the reaction was terminated and the majority of solvent was evaporated under reduced pressure. Proper water was added into the reaction mixture, and the product was extracted with ethyl acetate (3× 20 mL). The combined extracts were washed with saturated brine, dried with anhydrous sodium sulfate, and evaporated under reduced pressure. The residue was subjected to chromatography to produce 46 mg of 18a (73%) as pale yellow crystals, Â mp 158-159 • C; IR(KBr) (cm −1 ): 3276, 3066, 2933, 2864, 1629, 1466, 1376, 1291, 1237, 1200, 1134, 997, 967, 930, 857 (3E)- Yield 70%, Â mp 168-169 • C; IR(KBr) (cm −1 ): 3285, 3046, 2951, 2883, 1629, 1466, 1437, 1372, 1295, 1237, 1218, 1126, 995, 930, 873 
Cholest
24-Ethylcholest
